BioWorld, June 9, 2023: BioWorld news explains that FDA Advisory Committee supports Leqembi for Mild Cognitive Impairment (MCI) caused by Alzheimer’s and quotes our statement that MCI can go away without drugs, which means that Leqembi’s risks of brain swelling and bleeding will often greatly outweigh the potential benefits.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Lilly battling rivals for breast-cancer patients
Indianapolis Business Journal, June 9, 2023: We explain to the Indianapolis Business Journal that 3 drug companies are spending $millions to persuade breast cancer patients that their drug is best despite risky side effects. Their ads are confusing and misleading.
Read More »Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, June 1, 2023: CMS announces that Medicare will cover FDA fully approved Alzheimer’s treatments for patients in a registry that will evaluate safety and efficacy. NCHR explains why this is essential to learn which patients are most likely to benefit and which are most likely to be harmed.
Read More »Could new drugs for early Alzheimer’s really signal the end of dementia? These women say ‘breakthrough’ medicines have halted their mental decline. But do side-effects – and cost – outweigh the benefits…
Daily Mail, May 30, 2023: The Daily Mail reports on new Alzheimer’s drugs that are approved in the US but not in the UK. Dr. Zuckerman & other experts ask: Are they worth the costs or the risks? Patients want access but do these drugs really work? Mild cognitive impairment can change daily without treatment – we all have good days and bad days.
Read More »Under pressure from patients, FDA faces tough choices on experimental gene therapy
Boston Globe, May 22, 2023: Boston Globe quotes NCHR and other experts explaining why we are concerned that Sarepta’s gene therapy for Duchenne Muscular Dystrophy isn’t proven to work and has substantial risks. If it doesn’t work, patients who use it will not be able to try other, potentially better gene therapies in the future.
Read More »